Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors-Reference-Cited by-同舟云学术

Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors

Published:2019-04-01 Issue:4 Volume:5 Page:514
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

AlDubayan Saud H.¹²³⁴,Pyle Louise C.⁵⁶,Gamulin Marija⁷,Kulis Tomislav⁸,Moore Nathanael D.²,Taylor-Weiner Amaro²,Hamid Anis A.¹²,Reardon Brendan¹²,Wubbenhorst Bradley⁶,Godse Rama⁶,Vaughn David J.⁹,Jacobs Linda A.¹⁰,Meien Stefanie¹¹,Grgic Mislav⁷,Kastelan Zeljko⁸,Markt Sarah C.¹²,Damrauer Scott M.¹³,Rader Daniel J.¹⁴,Kember Rachel L.¹⁴,Loud Jennifer T.¹⁵,Kanetsky Peter A.¹⁶,Greene Mark H.¹⁵,Sweeney Christopher J.¹,Kubisch Christian¹¹,Nathanson Katherine L.⁶¹⁰,Van Allen Eliezer M.¹²,Stewart Douglas R.¹⁵,Lessel Davor¹¹,

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

2. Cancer Program, the Broad Institute of MIT and Harvard, Cambridge, Massachusetts

3. Division of Genetics, Brigham and Women’s Hospital, Boston, Massachusetts

4. Department of Medicine, King Saud bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia

5. Division of Human Genetics, Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

6. Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia

7. Division of Medical Oncology, Urogenital Unit, Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia

8. Department of Urology, University Hospital Center Zagreb, University of Zagreb, School of Medicine, Zagreb, Croatia

9. Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia

10. Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia

11. Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

12. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts

13. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia

14. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia

15. Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland

16. Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, Florida

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/4/514/17459122/jamaoncology_aldubayan_2019_oi_180113.pdf

Reference32 articles.

1. Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing.;Ruf;Urol Oncol,2014

2. Testicular cancer incidence to rise by 25% by 2025 in Europe? model-based predictions in 40 countries using population-based registry data.;Le Cornet;Eur J Cancer,2014

3. Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches.;Litchfield;Sci Rep,2015

4. Large-scale sequencing of testicular germ cell tumour (TGCT) cases excludes major TGCT predisposition gene.;Litchfield;Eur Urol,2018

5. The genomic landscape of testicular germ cell tumours: from susceptibility to treatment.;Litchfield;Nat Rev Urol,2016

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of the functional impact of single nucleotide variants of humanCHEK2;2023-12-23

2. CHEK2 deficiency increase the response to PD-1 inhibitors by affecting the tumor immune microenvironment;Cancer Letters;2023-12

3. Further Association of Germline CHEK2 Loss-of-Function Variants with Testicular Germ Cell Tumors;Journal of Clinical Medicine;2023-11-13

4. Testicular cancer in 2023: Current status and recent progress;CA: A Cancer Journal for Clinicians;2023-11-10

5. Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG);Genetics in Medicine;2023-10